Description
Latin name
VIASAN-LF
Release form
Film-coated tablets.
packaging 4 pcs – blisters (1) – packs of cardboard.
Indications
Treatment of erectile dysfunction characterized by an inability to achieve or maintain an erection of the penis sufficient for satisfactory intercourse.
Contraindications
Simultaneous administration of donors of nitric oxide or nitrates in any form, hypersensitivity to sildenafil.
Special instructions
Before starting sildenafil, a cardiovascular examination should be performed.
Caution should be used in patients with anatomical deformation of the penis (e.g., angulation, cavernous fibrosis, or Peyronie’s disease) and people with diseases that predispose to the development of priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
Should not be used in patients for whom sexual activity is undesirable.
Use with caution in patients with a tendency to bleeding, with peptic ulcer of the stomach and duodenum in the acute phase, with hereditary retinitis pigmentosa.
No evidence of carcinogenicity in sildenafil in experimental studies. Bacterial and in vivo mutagenicity tests were negative.
Influence on the ability to drive vehicles and control mechanisms
Sildenafil does not affect the ability to drive vehicles and control mechanisms.
For impaired renal function
For impaired renal function, the dose is 25 mg.
For impaired liver function
For impaired liver function, the dose is 25 mg.
Use in old age
For elderly patients over the age of 65, the dose is 25 mg.
Use in childhood.
Sildenafil is not used in patients under the age of 18 years.
Dosage and administration
Take orally about 1 hour before the planned sexual activity.
A single dose is 50 mg. Given the effectiveness and tolerability, the dose can be increased to 100 mg or reduced to 25 mg. The maximum single dose is 100 mg.
The maximum frequency of use is 1 time / day.
For elderly patients over the age of 65 and with concomitant impaired renal or hepatic function, the dose is 25 mg.
Side effects
From the side of the central nervous system: headache, flushing, dizziness, insomnia are possible.
From the digestive system: dyspepsia, asthenia, diarrhea, abdominal pain, nausea.
From the musculoskeletal system: arthralgia, myalgia, increased muscle tone.
From the respiratory system: nasal congestion, pharyngitis, rhinitis, sinusitis, respiratory tract infections, respiratory failure.
From the side of the organ of vision: a change in vision (a slight and transient mainly color change of objects, as well as increased perception of light and a violation of the clarity of vision), conjunctivitis.
Other: possible flu-like syndrome, the development of infectious diseases, symptoms of vasodilation, back pain, rash, urinary tract infection, impaired prostate function in rare cases – priapism.
Drug interaction
With the simultaneous use of CYP3A4 inhibitors (erythromycin, cimetidine), the clearance of sildenafil decreases, the concentration of sildenafil in the blood plasma increases.
With the simultaneous use of indinavir, saquinavir, ritonavir, Cmax in plasma and AUC of sildenafil rises, which is due to inhibition of the CYP3A4 isoenzyme under the influence of indinavir, saquinavir, ritonavir.
Stronger inhibitors of the CYP3A4 isoenzyme, such as ketoconazole or itraconazole, can be expected will increase the concentration of sildenafil in blood plasma
With simultaneous use with nitrates, the hypotensive effect of nitrates is enhanced.
A case of the development of symptoms of rhabdomyolysis after a single dose of sildenafil in a patient receiving simvastatin is described.
Terms and conditions
prescription
dosage form
tablets
